Market Overview

UPDATE: Citigroup Initiates Maximus at Buy on Health Care Reform Opportunities

Related MMS
Benzinga's Top Upgrades, Downgrades For May 25, 2017
Benzinga's Top Upgrades, Downgrades For May 5, 2017

Citigroup initiated coverage on Maximus (NYSE: MMS) with a Buy rating and a $75 price target.

Citigroup said, "Over the next three years, we think Maximus can more than double earnings. The company will continue to benefit from states moving fee for service Medicaid programs over to managed care. Moreover, Health Reform creates incremental growth opportunities from the Medicaid expansion and health exchanges. We think earnings can grow to $4.20 per share in 2015, and estimate the benefit of health exchanges and capital deployment could add another $0.70 per share."

Maximus closed at $63.09 on Monday.

Latest Ratings for MMS

May 2017KeyBancDowngradesOverweightSector Weight
May 2017JefferiesDowngradesBuyHold
Apr 2017Canaccord GenuityDowngradesBuyBuy

View More Analyst Ratings for MMS
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (MMS)

View Comments and Join the Discussion!